Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 8;30(5):oyaf072.
doi: 10.1093/oncolo/oyaf072.

Efficacy and safety of surufatinib in the treatment of thymic neuroendocrine tumors: a 102-case retrospective study

Xuebing Jia  1 , Zhichen Sun  1 , Junyan Xu  2 , Dan Huang  3 , Fengzhen Chen  1 , Jie Chen  1   4 , Yun Liang  1   4
Affiliations

Efficacy and safety of surufatinib in the treatment of thymic neuroendocrine tumors: a 102-case retrospective study

Xuebing Jia et al. Oncologist. .

Abstract

Introduction or hypothesis: The SANET-ep study confirmed that patients with non-pancreatic NET could benefit from surufatinib treatment compared with placebo. However, there is a lack of sufficient retrospective data on surufatinib's efficacy in treating thymic neuroendocrine tumors (TNETs). This study aimed to evaluate the efficacy and safety of surufatinib in well-differentiated TNETs by conducting a single center retrospective analysis.

Methods: We conducted a retrospective study at Fudan University Shanghai Cancer Center, including 102 patients with TNETs. This study assessed the efficacy and safety of surufatinib in this population.

Results: Median progression-free survival was 10.0 months, ORR was 5.6%, and DCR was 83.1%. Surufatinib performed better in first-line treatment compared to secondary treatment in terms of ORR, DCR, and mPFS. The most common adverse events were diarrhea (15.7%), hypertension (19.1%), proteinuria (13.5%), and hypothyroidism (5.6%). About 33.3% of patients required dosage reduction from 300 mg/day to 200 mg/day (or 250 mg/day) due to adverse events, which in most cases were mitigated or disappeared with dose reduction.

Conclusions: For patients with advanced, progressive, well-differentiated TNETs, Surufatinib can be used as an option with a high mPFS and DCR. Moreover, the safety profile of surufatinib was found to be acceptable. These findings suggest that surufatinib could potentially serve as an innovative therapeutic option for this particular patient population.

Keywords: neuroendocrine tumor; surufatinib; thymic; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1.
Figure 1.
Curve of progression-free survival analysis of 102 TNET patients and univariate analysis of progression-free survival. (A) Curve of progression-free survival analysis of 102 TNET patients. (B) Sex. (C) Age. (D) Functional status. (E) Ki-67 index. (F) Tumor grade. (G) Concurrent MEN. (H) Combined therapy. (I) Treatment lines. (J) Primary tumor resection. (K) Radiation therapy. (L) Immunology therapy
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Gaur P, Leary C, Yao JC.. Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann Surg. 2010;251:1117-1121. https://doi.org/10.1097/SLA.0b013e3181dd4ec4 - DOI - PubMed
    1. Ragnarsson O, Juhlin CC, Torpy DJ, Falhammar H.. A clinical perspective on ectopic Cushing’s syndrome. Trends Endocrinol Metab. 2024;35:347-360. https://doi.org/10.1016/j.tem.2023.12.003 - DOI - PubMed
    1. Simonds WF. Expressions of Cushing’s syndrome in multiple endocrine neoplasia type 1. Front Endocrinol. 2023;14:1183297. https://doi.org/10.3389/fendo.2023.1183297 - DOI - PMC - PubMed
    1. Thompson R, Landry CS.. Multiple endocrine neoplasia 1: a broad overview. Ther Adv Chronic Dis. 2021;12:20406223211035288. https://doi.org/10.1177/20406223211035288 - DOI - PMC - PubMed
    1. Guerrero-Pérez F, Peiró I, Marengo AP, et al.Ectopic Cushing’s syndrome due to thymic neuroendocrine tumours: a systematic review. Rev Endocr Metab Disord. 2021;22:1041-1056. https://doi.org/10.1007/s11154-021-09660-2 - DOI - PubMed